Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Avandia (Rosiglitazone) Clear all
Completed Phase 3 Interventional

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

NCT00182052
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Prostate Cancer
Interventions
Rosiglitazone, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 3 Interventional

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

NCT00138619
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
478 participants
Timeline
2004 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

NCT00110851
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rosiglitazone, metformin, PN2034
Drug
Lead sponsor
Wellstat Therapeutics
Industry
Eligibility
21 Years to 72 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
20
States / cities
Waterbury, Connecticut • DeLand, Florida • Hollywood, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced Oct 2, 2026, 2:32 AM EDT
Not listed Phase 2Phase 3 Interventional

PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions

NCT00116792
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
Gold, Herman K., MD
Individual
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2007 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 4 Interventional

Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome

NCT00364221
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance
Interventions
Rosiglitazone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

NCT00814255
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
17
States / cities
Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

NCT00381238
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Sun City, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 4 Interventional

Effect of Thiazolidinedione Treatment Vascular Risk Markers

NCT00571506
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Vascular Diseases
Interventions
Rosiglitazone, Pioglitazone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 2 Interventional

Rosiglitazone in Treating Patients With Liposarcoma

NCT00004180
View directory record Official record
Conditions
Sarcoma
Interventions
rosiglitazone maleate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 2, 2026, 2:32 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis

NCT00121953
View directory record Official record
Conditions
Endometriosis
Interventions
Rosiglitazone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)

NCT00081328
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Metformin, Rosiglitazone, Lifestyle Program
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
10 Years to 17 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
16
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL

NCT00178841
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
Interventions
Rosiglitazone and Bexarotene
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

NCT01402076
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tasimelteon, Rosiglitazone, Midazolam
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 2, 2026, 2:32 AM EDT
Terminated Phase 4 Interventional

Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study

NCT00343395
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AVANDAMET
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

NCT01060566
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2010 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 4 Interventional

Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

NCT00329225
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
130
States / cities
Birmingham, Alabama • Fairfield, Alabama • Fultondale, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 2, 2026, 2:32 AM EDT
Recruiting Phase 2 Interventional

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

NCT04114136
View directory record Official record
Conditions
Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
Interventions
Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 2 Interventional

Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia

NCT00006493
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
Rosiglitazone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Not applicable Interventional Results available

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

NCT00413335
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
10 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia

NCT00304993
View directory record Official record
Conditions
Metabolic Syndrome X, Insulin Resistance
Interventions
fenofibrate, niacin, rosiglitazone
Drug
Lead sponsor
Foundation Research, Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2006 · Synced Oct 2, 2026, 2:32 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

QTc Study of Rosi XR in Healthy Volunteers

NCT00884533
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosi XR, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 2, 2026, 2:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol

NCT00006071
View directory record Official record
Conditions
Hypercholesterolemia, Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 2:32 AM EDT
Completed Phase 3 Interventional

Rosiglitazone on Microalbuminuria in Type 2 Diabetics

NCT00500955
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
56
States / cities
Birmingham, Alabama • Tempe, Arizona • Fullerton, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 2, 2026, 2:32 AM EDT
Terminated Not applicable Interventional

Rosiglitazone-Induced Weight Gain

NCT00225225
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rosiglitazone, dietary recommendation for weight maintenance
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Oct 2, 2026, 2:32 AM EDT